<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102203</url>
  </required_header>
  <id_info>
    <org_study_id>NanjingJH01</org_study_id>
    <nct_id>NCT03102203</nct_id>
  </id_info>
  <brief_title>Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging</brief_title>
  <official_title>Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Prospective Multicenter Clinical Trial With Multimodality MR Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Jinling Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Jinling Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of multi-modality magnetic resonance quantitative parameters in
      evaluating the treatment effects of high-grade gliomas, and to provide new biomarkers for the
      establishment of new diagnostic criteria for the identification of true and pseudoprogression
      of high-grade gliomas.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ktrans</measure>
    <time_frame>baseline</time_frame>
    <description>The volume transfer constant in dynamic contrast-enhanced MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ktrans</measure>
    <time_frame>3 months</time_frame>
    <description>The volume transfer constant in dynamic contrast-enhanced MR Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ktrans</measure>
    <time_frame>10 months</time_frame>
    <description>The volume transfer constant in dynamic contrast-enhanced MR Imaging</description>
  </primary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Glioma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The Eligibility module specifies the criteria for determining which people are (or are not)
        eligible to participate in the study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with high-grade gliomas confirmed by pathology and have not been treated with
             concurrent chemoradiotherapy;

          2. Written informed consent is obtained.

        Exclusion Criteria:

          1. Patients not suitable for enhanced MRI scanning of patients;

          2. Patients who have not finished follow-up concurrent chemoradiotherapy or MR scanning.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guang Ming Lu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Jinling Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan Xie, Master</last_name>
    <phone>+86 13584099838</phone>
    <email>cheryl050914@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiqiang Zhang, Doctor</last_name>
      <phone>+86 13913885490</phone>
      <email>zhangzq2001@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Jinling Hospital</investigator_affiliation>
    <investigator_full_name>Lu Guang Ming</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

